* Please be kindly noted that our services and products can only be used for research to organizations or companies and not intended for any clinical or individuals.
BOC Sciences is a CRO that offers various services in the field of drug discovery. We provide HaloPROTAC technology development service includes the design, synthesis, and evaluation of HaloPROTACs. BOC Sciences has a team of experienced scientists and is able to work closely with clients to develop customized HaloPROTACs. Our service of HaloPROTAC can help accelerate the project of targeted protein degradation and to meet our customers'individual needs.
PROTAC (Proteolysis-Targeting Chimera) is a type of small molecule designed to selectively degrade disease-causing proteins within cells. PROTACs work by recruiting an E3 ubiquitin ligase to a target protein for its ubiquitination and proteasome-mediated degradation. The PROTAC molecule is bound to both the target protein and the E3 ligase in close enough proximity to form a ternary complex. PROTACs are able to target proteins that were previously considered undruggable, and also offer the potential for increased selectivity and reduced toxicity compared to small molecule inhibitors.
The HaloTag is a fusion protein that is a modified form of the haloalkane dehalogenase. HaloTag is a genetically encoded protein tag that can covalently bind to a range of synthetic ligands. HaloTag system has been widely used inmolecular biology to label and purify proteins. Furthermore, HaloTag protein labeling system has become a popular strategy used in PROTAC technology for selective protein degradation, that is HaloPROTAC. HaloPROTAC enables the selective degradation of proteins of interest, which has the potential to be used for therapeutic purposes.
The mechanism of action of HaloPROTAC:
* PROTAC® is a registered trademark of Arvinas Operations, Inc., and is used under license.
Please contact us with any specific requirements and we will get back to you as soon as possible.